Thermo Fisher Scientific Inc. $TMO Holdings Trimmed by Associated Banc Corp

Associated Banc Corp cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 44,415 shares of the medical research company’s stock after selling 862 shares during the quarter. Associated Banc Corp’s holdings in Thermo Fisher Scientific were worth $18,009,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Cornerstone Capital Inc. lifted its stake in Thermo Fisher Scientific by 6.0% during the second quarter. Cornerstone Capital Inc. now owns 50,205 shares of the medical research company’s stock valued at $20,356,000 after purchasing an additional 2,840 shares during the last quarter. Columbia Bank increased its holdings in shares of Thermo Fisher Scientific by 12.4% in the second quarter. Columbia Bank now owns 5,979 shares of the medical research company’s stock valued at $2,548,000 after buying an additional 658 shares in the last quarter. Laurel Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 27,971.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 29,194 shares of the medical research company’s stock valued at $11,837,000 after acquiring an additional 29,090 shares during the last quarter. RiverFront Investment Group LLC boosted its stake in shares of Thermo Fisher Scientific by 2.5% during the 2nd quarter. RiverFront Investment Group LLC now owns 4,571 shares of the medical research company’s stock worth $1,853,000 after acquiring an additional 113 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Thermo Fisher Scientific by 47.6% in the 2nd quarter. XTX Topco Ltd now owns 23,466 shares of the medical research company’s stock worth $9,515,000 after acquiring an additional 7,565 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO opened at $585.85 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The stock has a fifty day moving average price of $539.29 and a 200 day moving average price of $475.16. The stock has a market cap of $220.11 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. This trade represents a 1.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 41,845 shares of company stock valued at $23,947,352. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. TD Cowen raised their target price on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Wells Fargo & Company boosted their price target on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.